Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 6:22 pm Sale | 2024-09-30 | 13G | Edgewise Therapeutics, Inc. EWTX | EcoR1 Capital LLC | 1,250,385 1.300% | -2,242,809 (-64.21%) | Filing History |
| 2024-11-14 4:31 pm Sale | 2024-09-30 | 13G | Edgewise Therapeutics, Inc. EWTX | VIKING GLOBAL INVESTORS LP | 1,481,146 1.600% | -4,678,000 (-75.95%) | Filing History |
| 2024-11-14 4:14 pm Purchase | 2024-09-30 | 13G | Edgewise Therapeutics, Inc. EWTX | BAKER BROS. ADVISORS LP | 5,840,059 6.200% | 5,840,059 (New Position) | Filing History |
| 2024-11-14 08:59 am Sale | 2024-09-30 | 13G | Edgewise Therapeutics, Inc. EWTX | James E. Flynn | 1,781,006 1.900% | -2,697,586 (-60.23%) | Filing History |
| 2024-11-12 5:23 pm Unchanged | 2024-11-07 | 13D | Edgewise Therapeutics, Inc. EWTX | ORBIMED ADVISORS LLC | 14,756,096 15.600% | 0 (Unchanged) | Filing History |
| 2024-11-12 09:55 am Sale | 2024-11-08 | 13G | Edgewise Therapeutics, Inc. EWTX | FMR LLC | 653,207 0.696% | -4,127,355 (-86.34%) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Edgewise Therapeutics, Inc. EWTX | BlackRock Inc. BLK | 6,393,567 6.800% | 0 (Unchanged) | Filing History |
| 2024-10-22 6:06 pm Purchase | 2024-09-30 | 13G | Edgewise Therapeutics, Inc. EWTX | BlackRock Inc. BLK | 6,393,567 6.800% | 2,888,368 (+82.40%) | Filing History |
| 2024-09-23 9:20 pm Sale | 2024-09-19 | 13D | Edgewise Therapeutics, Inc. EWTX | Novo Holdings A/S | 5,549,900 5.900% | -794,530 (-12.52%) | Filing History |
| 2024-07-10 10:10 am Sale | 2024-07-09 | 13G | Edgewise Therapeutics, Inc. EWTX | FMR LLC | 4,780,562 5.118% | -1,711,951 (-26.37%) | Filing History |
| 2024-02-14 10:26 am Purchase | 2023-12-31 | 13G | Edgewise Therapeutics, Inc. EWTX | VIKING GLOBAL INVESTORS LP | 6,159,146 9.700% | 1,750,000 (+39.69%) | Filing History |
| 2024-02-14 08:43 am Sale | 2023-12-31 | 13G | Edgewise Therapeutics, Inc. EWTX | Deep Track Capital, LP | 2,537,176 4.000% | -837,218 (-24.81%) | Filing History |
| 2024-02-09 09:03 am Sale | 2024-02-08 | 13G | Edgewise Therapeutics, Inc. EWTX | FMR LLC | 6,492,513 10.230% | -2,096,716 (-24.41%) | Filing History |
| 2024-02-07 5:09 pm Purchase | 2024-01-31 | 13G | Edgewise Therapeutics, Inc. EWTX | BlackRock Inc. BLK | 3,505,199 4.100% | 198,089 (+5.99%) | Filing History |
| 2024-02-02 3:57 pm Purchase | 2023-12-31 | 13G | Edgewise Therapeutics, Inc. EWTX | BlackRock Inc. BLK | 3,307,110 5.200% | 3,307,110 (New Position) | Filing History |
| 2024-02-01 5:28 pm Purchase | 2024-01-23 | 13G | Edgewise Therapeutics, Inc. EWTX | James E. Flynn | 4,478,592 5.250% | 545,455 (+13.87%) | Filing History |
| 2024-01-29 4:30 pm Purchase | 2024-01-19 | 13G | Edgewise Therapeutics, Inc. EWTX | RA CAPITAL MANAGEMENT L.P. | 8,909,091 9.600% | 8,909,091 (New Position) | Filing History |
| 2024-01-25 4:26 pm Purchase | 2024-01-23 | 13D | Edgewise Therapeutics, Inc. EWTX | Novo Holdings A/S | 6,344,430 7.400% | 272,727 (+4.49%) | Filing History |
| 2024-01-25 4:25 pm Purchase | 2024-01-23 | 13D | Edgewise Therapeutics, Inc. EWTX | ORBIMED ADVISORS LLC | 14,756,096 17.300% | 454,545 (+3.18%) | Filing History |
| 2023-06-28 4:17 pm Unchanged | 2023-06-19 | 13D | Edgewise Therapeutics, Inc. EWTX | Novo Holdings A/S | 6,071,703 9.600% | 0 (Unchanged) | Filing History |